IR in IPOs of early-stage biotech companies: from scientific hypothesis to investor trust
IPO for biotech startups is a test of trust formed by IR: trust in science, in technology, in the team, in the company’s ability to build transparent, sustainable communication with the market.
The right IR strategy turns a high-risk placement into a market success. The combination of IPO and IR is critical for biotech. Investor Relations in biotechnology is a tool for shaping the perception of scientific history.
One of the tasks of IR in the framework of IPO is to translate scientific and technical information into the language of value for the investor.
News from www.ir7.com